A5020448557- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- Nutrition and Health in Aging
- Nausea and vomiting management
- RNA modifications and cancer
- Neuroblastoma Research and Treatments
- Pancreatic and Hepatic Oncology Research
Shizuoka Cancer Center
2016-2025
Keio University
1973-2022
Thoracic Surgery Foundation
2012-2022
National Cancer Center Hospital East
2008-2021
National Hospital Organization Kyushu Cancer Center
2020
Northwestern Medicine
2014
Cancer Genetics (United States)
2014
Japan Clinical Cancer Research Organization
2014
Fukushima Medical University
2010
Kumamoto University
2010
8500 Background: Adjuvant platinum-based chemotherapy (chemo) provides only a modest 5-year survival benefit in fully resected, high-risk early-stage NSCLC. We report the primary disease-free (DFS) results from pre-planned interim analysis of IMpower010, randomized phase 3 open-label trial adjuvant atezolizumab (atezo; anti–PD-L1) vs best supportive care (BSC) after chemo patients (pts) with resected Methods: Eligible pts had completely (4-12 weeks prior to enrollment) Stage IB (≥4 cm)-IIIA...
IntroductionTo evaluate the efficacy and safety of osimertinib plus bevacizumab for previously untreated patients with advanced nonsquamous NSCLC harboring EGFR-sensitizing mutations.MethodsWe conducted a randomized, open-label, phase 2 study at 21 institutions in Japan. Previously mutations received either (80 mg, daily) (15 mg/kg, every 3 wk) or monotherapy, were stratified according to sex, stage, EGFR mutation status. The primary end point was progression-free survival (PFS)...
Enumeration of circulating tumor cells (CTCs) may be valuable for prognostic assessment in lung cancer patients. In this study, we report the clinical significance CTCs small cell (SCLC).In total, 51 consecutive patients newly diagnosed as having SCLC and starting chemotherapy or chemoradiotherapy were prospectively enrolled. Blood samples drawn at baseline, after chemotherapy, relapse. isolated using CellSearch System (Veridex LLC). Thresholds 1 to 100 baseline systematically correlated...
Background Epithelial cell adhesion molecule (EpCAM)-based enumeration of circulating tumor cells (CTC) has prognostic value in patients with solid tumors, such as advanced breast, colon, and prostate cancer. However, poor sensitivity been reported for non-small lung cancer (NSCLC). To address this problem, we developed a microcavity array (MCA) system integrated miniaturized device CTC isolation without relying on EpCAM expression. Here, report the results clinical study CTCs which compared...
The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because only a small percentage enrolled in the clinical trials to evaluate tumors EGFR mutation were NSCLC. A pooled analysis was conducted clarify NSCLC mutations. systematic search PUBMED databases identify all reports that contained advanced and treated gefitinib. selected who described containing data histology, status...
PURPOSE To evaluate the efficacy of pemetrexed plus cisplatin versus vinorelbine as postoperative adjuvant chemotherapy in patients with pathologic stage II-IIIA nonsquamous non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS We performed a randomized, open-label, phase III study at 50 institutions within 7 clinical groups Japan. Patients completely resected (TNM 7th edition) NSCLC were randomly assigned to receive either (500 mg/m 2 , day 1) (75 or (25 days 1 and 8) (80 stratification...
Although third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitors ( EGFR ‐ TKI ) can overcome T790M‐mediated resistance in non‐small‐cell lung cancer NSCLC ), rebiopsy to confirm T790M status is occasionally difficult. We aimed investigate the current tendency and limitations of clinical practice. This study included 139 consecutive patients with mutations, who had experienced progressive disease PD after treatment. retrospectively reviewed patient characteristics, tumor...
Osimertinib has been reported to be effective against central nervous system (CNS) metastasis from activating EGFR mutation-positive NSCLC. Nevertheless, the true antitumor effects of osimertinib alone for CNS are unclear because aforementioned studies included previously irradiated cases, in which tumor shrinkage can occur later owing radiotherapy (RT). This study aimed evaluate efficacy RT-naive sensitizing NSCLC.The OCEAN was a two-cohort trial, involving 66 patients (T790M cohort [n =...
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease implicated as an independent risk factor for cancer. However, optimal treatment advanced cancer with IPF remains to be established. We performed randomised phase 3 trial (J-SONIC) assess the efficacy and safety of nintedanib plus chemotherapy (experimental arm) compared alone (standard-of-care nonsmall cell (NSCLC) IPF.Chemotherapy-naïve NSCLC patients were allocated receive carboplatin (area under curve 6 on day 1) nanoparticle...
LBA8035 Background: IMpower010 (NCT02486718) met its primary endpoint of significant DFS improvement with atezo vs BSC after adj chemotherapy in resected NSCLC the PD-L1 TC ≥1% and all-randomized stage II-IIIA populations, leading to worldwide approval for or ≥50% NSCLC. At OS IA1, a trend favoring was seen population. Here we report findings from FA IA2. Methods: The study design has been previously described (Felip et al, Lancet 2021). secondary endpoints were tested hierarchically:...
In this study, we present a method for efficient enrichment of small-sized circulating tumor cells (CTCs) such as those found in the blood small-cell lung cancer (SCLC) patients using microcavity array (MCA) system. To enrich CTCs from whole blood, microfabricated nickel filter with rectangular MCA (10(4) cavities/filter) was integrated miniaturized device, allowing isolation based on differences size and deformability between cells. The shape porosity were optimized to efficiently capture...
BACKGROUND Integration of mutational profiling to identify driver genetic alterations in a clinical setting is necessary facilitate personalized lung cancer medicine. A tumor genotyping panel was developed and the Shizuoka Lung Cancer Mutation Study initiated as prospective study. This study reports frequency Japanese adenocarcinoma patients, clinicopathologic correlations with each genotype. METHODS Between July 2011 January 2013, 411 patients admitted Center were included this their...
Elderly patient with advanced cancer is one of the most vulnerable populations. Skeletal muscle depletion during chemotherapy may have substantial impact on their physical function. However, there little information about a direct relationship between quantity and We sought to explore quantitative association skeletal depletion, strength walking capacity in elderly patients non-small cell lung (NSCLC).Thirty aged ≥70 years NSCLC (stage III-IV) scheduled initiate first-line were prospectively...
Abstract The prognosis of non‐small‐cell lung cancer (NSCLC) patients with interstitial disease (ILD) is poor, and 5%‐20% those receiving chemotherapy experience ILD exacerbation. To evaluate the safety efficacy nab‐paclitaxel plus carboplatin for NSCLC ILD, we undertook a multicenter phase II study. Chemotherapy‐naïve advanced mild or moderate received (100 mg/m 2 , days 1, 8, 15) (area under curve = 6, day 1) every 3 weeks 4 cycles (maximum, 6 cycles). Interstitial diseases were diagnosed...
IntroductionProgrammed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies focused on the impact of cancer cachexia efficacy PD-1 or programmed death-ligand (PD-L1) among NSCLC.MethodsWe retrospectively reviewed medical records NSCLC who received PD-L1 inhibitor monotherapy from May 2016 to December 2018. We defined as unintentional weight loss greater than 5% over 6 months and high 50% expression tumor cells. evaluated...